Search Result

Results for "

alk5+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Anaplastic lymphoma kinase (ALK) (7) Isotope-Labeled Compounds (1) Organoid (2) p38 MAPK (1) Reference Standards (3) TGF-beta/Smad (4) TGF-β Receptor (33)
By Research Areas:	Cancer (28) Cardiovascular Disease (2) Inflammation/Immunology (12) Metabolic Disease (7) Neurological Disease (1)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Isotope-Labeled Compounds

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13012

RepSox Maximum Cited Publications 21 Publications Verification E-616452; SJN 2511	Organoid TGF-β Receptor	Metabolic Disease
RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC₅₀ value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .

HY-12043

SB 525334 15+ Cited Publications	TGF-β Receptor	Cancer
SB 525334 is a potent and selective transforming growth factor β1 receptor *(ALK5)* inhibitor with an IC₅₀ of 14.3 nM.

HY-19928

Vactosertib 5+ Cited Publications EW-7197; TEW-7197	TGF-β Receptor	Cancer
Vactosertib (EW-7197) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC₅₀ of 12.9 nM. Vactosertib also inhibits ALK2 and ALK4 (IC₅₀ of 17.3 nM) at nanomolar concentrations. Vactosertib has potently antimetastatic activity and anticancer effect .

HY-13012G

RepSox E-616452; SJN 2511	TGF-β Receptor	Metabolic Disease
RepSox (E-616452) (GMP) is a RepSox (HY-13012) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. RepSox is a potent and selective TGF-β-RI/ALK5 inhibitor .

HY-13227

SD-208 5+ Cited Publications	TGF-β Receptor	Cancer
SD-208 is a selective TGF-βRI (ALK5) inhibitor with IC₅₀ of 48 nM, and > 100-fold selectivity over TGF-βRII.

HY-103021

LY3200882 10+ Cited Publications	TGF-β Receptor	Inflammation/Immunology Cancer
LY3200882 is a potent, highly selective, ATP-competitive and orally active TGF-β receptor type 1 (ALK5) inhibitor with an IC₅₀ of 38.2 nM. LY3200882 inhibits various pro-tumorigenic activities and is also used as an immune modulatory agent .

HY-12953

R-268712	TGF-β Receptor TGF-beta/Smad Anaplastic lymphoma kinase (ALK)	Cardiovascular Disease Inflammation/Immunology Cancer
R-268712 is an orally active and selective *ALK-5* inhibitor, with an IC₅₀ of 2.5 nM. R-268712 inhibits the phosphorylation of Smad3 in a dose-dependent manner with an IC₅₀ of 10.4 nM. R-268712 suppresses glomerulonephritis as well as glomerulosclerosis by inhibiting TGF-β signaling, which can be used in studies of renal fibrosis and cancer .

HY-19928A

Vactosertib Hydrochloride 5+ Cited Publications EW-7197 Hydrochloride; TEW-7197 Hydrochloride	TGF-β Receptor	Cancer
Vactosertib Hydrochloride (EW-7197 Hydrochloride) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC₅₀ of 12.9 nM. Vactosertib Hydrochloride also inhibits ALK2 and ALK4 (IC₅₀ of 17.3 nM) at nanomolar concentrations. Vactosertib Hydrochloride has potently antimetastatic activity and anticancer effect .

HY-10327

GW-6604	TGF-β Receptor	Metabolic Disease
GW-6604 is an *ALK5* inhibitor with an IC₅₀ value of 140 nM for inhibiting its autophosphorylation, and can be used in the study of liver fibrosis .

HY-150169

THRX-144644	TGF-β Receptor	Cancer
THRX-144644 is a Lung-restricted *ALK5* inhibitor with an IC₅₀ value of 0.14 nM. THRX-144644 avoids systemic toxicities associated with TGFβ pathway inhibition .

HY-18758

IN-1130 1 Publications Verification	TGF-β Receptor	Inflammation/Immunology Cancer
IN-1130 is a highly selective transforming growth factor-β type I receptor kinase (ALK5) inhibitor with an IC₅₀ of 5.3 nM for ALK5-mediated Smad3 phosphorylation. IN-1130 inhibits ALK5 phosphorylation of casein (IC₅₀=36 nM) and p38α mitogen-activated protein kinase (IC₅₀=4.3 μM). IN-1130 suppresses renal fibrosis in obstructive nephropathy and blocks breast cancer lung metastasis .

HY-13783

BIBF0775	TGF-β Receptor	Cancer
BIBF0775 is a potent and selective transforming growth factor β (TGFβ) type I receptor (Alk5) inhibitor with an IC₅₀ of 34 nM.

HY-125851

TP-008	TGF-β Receptor	Inflammation/Immunology
TP-008, a chemical probe, is a potent, selective and orally active (Activin-Like Kinase 5) ALK5 inhibitor with pIC₅₀ and pEC₅₀ values of 7.6 and 6.63, respectively. TGFβRI-IN-2 can produce observed cardiac toxicity in vivo at high dose .

HY-151275

ALK5-IN-28	TGF-β Receptor TGF-beta/Smad	Cancer
ALK5-IN-28 (Compound Ex-05) is a selective *ALK-5* inhibitor (IC₅₀ ≤ 10 nM) that inhibits TGF-β-induced SMAD signaling. ALK5-IN-28 has the potential to inhibit tumor growth in vivo. ALK5-IN-28 can be used in the research of proliferative diseases such as cancer .

HY-151283

ALK5-IN-33	TGF-β Receptor	Cancer
ALK5-IN-33 (Compound EX-10) is a selective, orally active *ALK-5* inhibitor with an IC₅₀ ≤10 nM .

HY-178231

ALK5-IN-85	TGF-β Receptor	Inflammation/Immunology Cancer
ALK5-IN-85 (Compound 19) is a TGFβRI (ALK5) inhibitor with an IC₅₀ < 100 ?nM. ALK5-IN-85 can be used for respiratory diseases including idiopathic pulmonary fibrosis, asthma, COPD and lumg cancer, and dermal and ocular fibrotic conditions research .

HY-161662

ALK5-IN-80	TGF-β Receptor	Cancer
ALK5-IN-80 (Compound 29b) is a selective *ALK5* inhibitor with an IC₅₀ value of 3.7 nM. ALK5-IN-80 can be used for cancer research .

HY-13012R

RepSox (Standard) E-616452 (Standard); SJN 2511 (Standard)	Organoid TGF-β Receptor Reference Standards	Metabolic Disease
RepSox (Standard) is the analytical standard of RepSox. This product is intended for research and analytical applications. RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC50 value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .

HY-159952

ALK5-IN-84	Anaplastic lymphoma kinase (ALK)	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
ALK5-IN-84 (Compound 23) is an ALK5 inhibitor with a pK_i value of 9.35 against *hALK5. When administered via inhalation, ALK5-IN-84* exhibits significant *ALK5* inhibitory activity. ALK5-IN-84 is promising for the development of inhaled *ALK5* inhibitors .

HY-112877

ALK-5-IN-1	TGF-β Receptor	Cancer
ALK-5-IN-1 is an *ALK-5* inhibitor. ALK-5-IN-1 can be used for the research of cancer, and conditions involving fibrosis .

HY-107386

PF-03671148	Anaplastic lymphoma kinase (ALK)	Others
PF-03671148 is an *ALK5* inhibitor. PF-03671148 can reduce TGFβ induced fibrotic gene expression in fibroblasts. PF-03671148 has potential utility for the prevention of dermal scarring .

HY-149403

J-1048	Anaplastic lymphoma kinase (ALK)	Others
J-1048 is an activin receptor-like kinase 5 *(ALK5)* inhibitor. J-1048 can inhibit TAA-induced liver fibrosis in mice by explicitly blocking the TGF-β/Smad signaling pathway .

HY-13227R

SD-208 (Standard)	TGF-β Receptor	Cancer
SD-208 (Standard) is the analytical standard of SD-208. This product is intended for research and analytical applications. SD-208 is a selective TGF-βRI (ALK5) inhibitor with IC50 of 48 nM, and > 100-fold selectivity over TGF-βRII.

HY-151273

ALK5-IN-27	TGF-β Receptor	Cancer
ALK5-IN-27 (Compound EX-04) is a potent *ALK-5* inhibitor with an IC₅₀ ≤10 nM. ALK5-IN-27 also inhibits ALK-2 (selectivity ALK2/ALK5 ≤10) .

HY-168607

ALK5-IN-83	TGF-beta/Smad	Cancer
ALK5-IN-83 (compound 13b) is a *ALK5* inhibitor with the IC₅₀ of 0.13 μM. ALK5-IN-83 inhibits TGF-β1-induced Smad2 phosphorylation and cell motility in A549 cells .

HY-145855

J-1063	TGF-β Receptor	Inflammation/Immunology
J-1063 is a potent, selective and orally active *ALK5* inhibitor with an IC₅₀ of 0.039 µM. J-1063 shows anti-fibrotic effect by the inhibition of inflammatory infiltration, collagen deposition, and hepatocytes necrosis. J-1063 has the potential for the research of liver fibrosis .

HY-163429

J-1149	TGF-β Receptor p38 MAPK	Inflammation/Immunology Cancer
J-1149 is a potent *ALK5* inhibitor, with an IC₅₀ value of 0.017 μM. J-1149 also shows weak p38α MAP kinase inhibitory activity, with an IC₅₀ value of 0.435 μM. J-1149 can be used for liver fibrosis research .

HY-151233

ALK5-IN-10	TGF-β Receptor	Cancer
ALK5-IN-10 (Compound 5d) is a TGF-β type I receptor kinase *ALK5* inhibitor, with IC₅₀s of 0.007 and 1.98 μM for ALK5 and p38α, respectively. ALK5-IN-10 can be used for the research of cancer .

HY-151270

ALK5-IN-25	TGF-β Receptor	Cancer
ALK5-IN-25 (compound EX-02) is a potent *ALK-5* inhibitor with an IC₅₀ ≤10 nM.ALK5-IN-25 also inhibits ALK-2 (selectivity ALK2/ALK5≤10). ALK5-IN-25 can be used for the research of cancer .

HY-151281

ALK5-IN-31	TGF-β Receptor	Cancer
ALK5-IN-31 (compound Ex-08) is a selective *ALK-5* inhibitor (IC₅₀≤10 nM), inhibits TGF-β-induced SMAD signaling. ALK5-IN-31 has the potential to inhibit growth of tumour in vivo. ALK5-IN-31 can be used in study of proliferative diseases such as cancer, fibrotic diseases, and systemic sclerosis .

HY-151282

ALK5-IN-32	TGF-β Receptor TGF-beta/Smad	Cancer
ALK5-IN-32 (compound EX-09) is a selective *ALK-5* inhibitor (10 nM<IC₅₀<100 nM), inhibits TGF-β-induced SMAD signaling. ALK5-IN-32 has the potential to inhibit growth of tumour in vivo. ALK5-IN-32 can be used in study of proliferative diseases such as cancer, fibrotic diseases, and systemic sclerosis .

HY-18758R

IN-1130 (Standard)	TGF-β Receptor	Inflammation/Immunology Cancer
IN-1130 (Standard) is the analytical standard of IN-1130. This product is intended for research and analytical applications. IN-1130 is a highly selective transforming growth factor-β type I receptor kinase (ALK5) inhibitor with an IC50 of 5.3 nM for ALK5-mediated Smad3 phosphorylation. IN-1130 inhibits ALK5 phosphorylation of casein (IC50=36 nM) and p38α mitogen-activated protein kinase (IC50=4.3 μM). IN-1130 suppresses renal fibrosis in obstructive nephropathy and blocks breast cancer lung metastasis .

HY-182547

LY580276	Anaplastic lymphoma kinase (ALK)	Cancer
LY580276 is an ATP-competitive *ALK5* inhibitor with an IC₅₀ of 175 nM. LY580276 inhibits transforming growth factor-β-induced epithelial-mesenchymal transition. LY580276 can be used for cancer research .

HY-10327R

GW-6604 (Standard)	Reference Standards TGF-β Receptor	Metabolic Disease
GW-6604 (Standard) is the analytical standard of GW-6604 (HY-10327). This product is intended for research and analytical applications. GW-6604 is an ALK5 inhibitor with an IC₅₀ value of 140 nM for inhibiting its autophosphorylation, and can be used in the study of liver fibrosis .

HY-183950

ALK5-IN-87	Anaplastic lymphoma kinase (ALK)	Inflammation/Immunology
ALK5-IN-87 is a potent lung-restricted *ALK5* inhibitor with a pK_i of 10.13. ALK5-IN-87 exerts antifibrotic activity in a mouse model of lung fibrosis. ALK5-IN-87 can be used for the research of idiopathic pulmonary fibrosis .

HY-13227G

SD-208	TGF-β Receptor	Cancer
SD-208 (GMP) is SD-208 (HY-13227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SD-208 is a selective TGF-βRI (ALK5) inhibitor with IC₅₀ of 48 nM, and > 100-fold selectivity over TGF-βRII.

HY-181139

ALK5-IN-86	Anaplastic lymphoma kinase (ALK)	Metabolic Disease
ALK5-IN-86 (Compound 22f) is a selective *ALK5* inhibitor with an IC₅₀ of 0.267 μM. ALK5-IN-86 forms hydrogen bonds with key amino acid residues in the active site of ALK5. ALK5-IN-86 is applicable to the research of diseases such as liver fibrosis .

HY-103021R

LY3200882 (Standard)	Reference Standards TGF-β Receptor	Inflammation/Immunology Cancer
LY3200882 (Standard) is the analytical standard of LY3200882 (HY-103021). This product is intended for research and analytical applications. LY3200882 is a potent, highly selective, ATP-competitive and orally active TGF-β receptor type 1 (ALK5) inhibitor with an IC₅₀ of 38.2 nM. LY3200882 inhibits various pro-tumorigenic activities and is also used as an immune modulatory agent .

HY-13012S

RepSox-d5 E-616452-d₅; SJN 2511-d₅	Isotope-Labeled Compounds TGF-β Receptor	Metabolic Disease
RepSox-d₅ (E-616452-d₅) is the deuterium labeled RepSox (HY-13012). RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC₅₀ value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .

HY-185430

HM-279	TGF-β Receptor	Inflammation/Immunology Cancer
HM-279 is a potent and orally active *ALK5* inhibitor with an IC₅₀ of 4.7 nM. HM-279 shows cross-reactivity with ALK7 (IC₅₀ = 6.8 nM), but HM-279 has fair to good selectivity against other TGF-β receptor family kinases, with 4.5-693-fold selectivity. HM-279 demonstrates antitumor activity in vivo through CD8 ⁺ T cell immunity. HM-279 can be used for the research of colon cancer .

Cat. No.	Product Name	Type

HY-13012G

RepSox E-616452; SJN 2511	Fluorescent Dyes
RepSox (E-616452) (GMP) is a RepSox (HY-13012) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. RepSox is a potent and selective TGF-β-RI/ALK5 inhibitor .

HY-13227G

SD-208	Fluorescent Dyes
SD-208 (GMP) is SD-208 (HY-13227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SD-208 is a selective TGF-βRI (ALK5) inhibitor with IC₅₀ of 48 nM, and > 100-fold selectivity over TGF-βRII.

Cat. No.	Product Name	Type

HY-13012G

RepSox E-616452; SJN 2511	Biochemical Assay Reagents
RepSox (E-616452) (GMP) is a RepSox (HY-13012) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. RepSox is a potent and selective TGF-β-RI/ALK5 inhibitor .

HY-13227G

SD-208	Biochemical Assay Reagents
SD-208 (GMP) is SD-208 (HY-13227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SD-208 is a selective TGF-βRI (ALK5) inhibitor with IC₅₀ of 48 nM, and > 100-fold selectivity over TGF-βRII.

Cat. No.	Product Name	Chemical Structure

HY-13012S

RepSox-d5

RepSox-d₅ (E-616452-d₅) is the deuterium labeled RepSox (HY-13012). RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC₅₀ value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13012G

RepSox E-616452; SJN 2511	TGF-β Receptor	Metabolic Disease
RepSox (E-616452) (GMP) is a RepSox (HY-13012) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. RepSox is a potent and selective TGF-β-RI/ALK5 inhibitor .

HY-13227G

SD-208	TGF-β Receptor	Cancer
SD-208 (GMP) is SD-208 (HY-13227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SD-208 is a selective TGF-βRI (ALK5) inhibitor with IC₅₀ of 48 nM, and > 100-fold selectivity over TGF-βRII.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: